Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

  • End date
    Dec 15, 2028
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 21 August 2021
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (3.7 mi away) Contact
+99 other location


To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)


The study is divided into a Core Phase, which includes the Double-Blind Treatment Period, and an Extension Phase in which all patients will be treated with fingolimod. The Core Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN -1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is a 60-month (5 year) study phase for patients who complete the Core Phase of the study and meet all inclusion/exclusion criteria and for patients who will be recruited in the younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the population of pediatric patients fulfilling any single one or a combination of the following criteria: being 12 years of age, or weighing 40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2). The recruitment of the younger cohort (30 patients) was requested as a post- approval health authority commitment

Condition Multiple Sclerosis, Radiologically Isolated Syndrome, Dermatite Atopique modérée ou grave, multiple sclerosis (ms)
Treatment Placebo Capsule, Interferon beta-1a i.m. injections, Fingolimod oral capsules, Placebo oral capsule, Placebo i.m. injection, Fingolimod, Interferon beta-1a
Clinical Study IdentifierNCT01892722
SponsorNovartis Pharmaceuticals
Last Modified on21 August 2021


Yes No Not Sure

Inclusion Criteria

Applies to all patients participating in the Core Phase and then entering the
Extension Phase. 1. Patients that originally met Core Phase Inclusion criteria
and completed the Core phase on or off of study drug
Applies to patients newly recruited to participate in the Extension Phase
All newly recruited patients' that enroll directly into the Extension Phase must fulfill the local country health authority product label approved for pediatric age group for inclusion criteria
Central review (including initial MRI report) of the diagnosis of pediatric MS will be required for all newly recruited patients

Exclusion Criteria

Applies to patients who completed the Core Phase, but prematurely discontinued
study drug
Premature discontinuation of the study drug during the Core Phase due to
an adverse event
serious adverse event
laboratory abnormality
other conditions leading to permanent study drug discontinuation due to safety reasons
Patients with known new events or concomitant medications (washout periods required prior to Visit 15) that would exclude them from the Core Phase exclusion criteria. Serological or other additional tests will not be required
Applies to patients newly recruited in the younger cohort to participate in
the Extension Phase
All newly recruited patients in the younger cohort that enroll directly into the Extension Phase must fulfill the exclusion criteria for the core phase
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note